This is an interesting proposal — requesting 38 trials through YODA in addition to about 200 trials the authors already have access to. My major concern is that we have few detail on the diseases and outcomes of interest. The authors provide diabetes as an example but then claim at HbA1c is the outcome of interest. Why look at a surrogate like HbA1c (for which there is surely heterogeneity based on clinical comorbidities) instead of looking at clinical endpoints (CV death, MI, stroke).Not Approve
I would respectfully ask the authors to supply additional details.